✦ LIBER ✦

Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support

✍ Scribed by Gini F. Fleming; Linda Janisch; Nicholas J. Vogelzang; Everett E. Vokes; Mark J. Ratain

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 443 KB
Volume: 77
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19960601)77:11<2308::aid-cncr19>3.0.co;2-0

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

Both paclitaxel and mitoxantrone demonstrate significant antineoplastic activity in breast cancer patients. Colony stimulating factor support allows significant dose escalation of each of these drugs when administered as a single agent.

METHODS.

We performed a Phase I study employing escalating doses of paclitaxel and mitoxantrone with granulocyte-macrophage colony stimulating factor (GM-CSF) support. Initially the paclitaxel dose was fixed at 175 mg/m2 and an attempt was made to escalate mitoxantrone from the starting dose of 14 mglm'. Subsequently, the dose of mitoxantrone was fixed at 14 mg/m2 and the dose of paclitaxel was increased. Treatments were given every three weeks.

📜 SIMILAR VOLUMES

A Phase I dose escalation of combination

A Phase I dose escalation of combination chemotherapy with granulocyte-macrophage–colony stimulating factor in patients with neuroblastoma

✍ M. Carmen Fernandez; Mark D. Krailo; Robert R. Gerbing; Katherine K. Matthay 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

Phase I study of vinorelbine and paclita

Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma

✍ Nuhad K. Ibrahim; Aman U. Buzdar; Vicente Valero; Kapil Dhingra; Jie Willey; Gab 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

A phase I trial of ifosfamide and paclit

A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors

✍ Craig A. Bunnell; Lynn Thompson; Lori Buswell; Ross Berkowitz; Michael Muto; Ell 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 1 views

## Background: Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. a phase i trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. ## Methods: Patients with refra

Phase II trial of subcutaneously adminis

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

A Phase II intra-patient dose-escalation

A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes

✍ Jason Gotlib; Philip Lavori; Sylvia Quesada; Richard S. Stein; Shahin Shahnia; P 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

Phase I trial of paclitaxel, carboplatin

Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer

✍ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that